Q-omics provides the consensus-scored DPAGT1 profile across patient tissues and cancer cell-line models. DPAGT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, DPAGT1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, DPAGT1 RNA expression shows 18,976 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, BLCA, and ACC as cancer lineages where DPAGT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPAGT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPAGT1 survival associations across molecular data types. DPAGT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPAGT1 RNA expression–survival associations across cancer types. High DPAGT1 expression shows unfavorable associations in LGG, UVM, ACC, LIHC and BRCA, but favorable associations in STAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for DPAGT1 RNA expression.
This table summarizes DPAGT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DPAGT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPAGT1 shows higher tumor expression in BLCA, HNSC, STAD, COAD, LIHC and LUAD. The BLCA box plot shows higher DPAGT1 RNA expression in tumor versus normal tissue (log2 FC = +0.952, t-test p < 0.001).
This table shows molecular features associated with DPAGT1 in patient tissues and cancer cell lines. In patient samples, DPAGT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPAGT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
